Carl Zeiss Meditec AG is rated Strong Buy with higher share price target, undervaluation & robust fundamentals. Read more on ...

Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment JENA, Germany, Dec. 15, 2023 /PRNewswire/ -- Carl ...

Fintel reports that on August 5, 2024, METZLER EQUITIES upgraded their outlook for Carl Zeiss Meditec AG - Depositary Receipt () (OTCPK:CZMWY) from Hold to Buy. As of August 6, 2024, the average ...

Carl Zeiss Meditec AG's ( ETR:AFX ) dividend is being reduced from last year's payment covering the same period ...

Fintel reports that on August 6, 2024, MWB RESEARCH AG upgraded their outlook for Carl Zeiss Meditec (XTRA:AFX) from Hold to Buy. As of August 5, 2024, the average one-year price target for Carl Zeiss ...

EQS Preliminary announcement financial reports: Carl Zeiss Meditec AG / Preliminary announcement on the disclosure of financial statements Carl Zeiss Meditec AG: Preliminary announcement of the ...

If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly ...

EQS-News: Carl Zeiss Meditec AG / Key word(s): Quarterly / Interim Statement/Quarter Results Carl Zeiss Meditec achieves slight revenue growth in first three months of 2024/25 12.02.2025 / 06:58 ...

Please provide your email address to receive an email when new articles are posted on . Carl Zeiss Meditec AG will acquire Dutch Ophthalmic Research Center in 2024. The transaction is valued at ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

DUBLIN, Calif. & JENA, Germany--(BUSINESS WIRE)--"While our focus has been on intraoperative radiotherapy for breast cancer, we now also offer patented radiation technology for patients with skin or ...

LONDON, Feb 4 (Reuters) - Optics specialist Carl Zeiss AG is poised to prop up its eyeglass lens maker Carl Zeiss Vision with a second equity injection which will dilute the shareholding of private ...